- Home
- EQS vs CLRB Comparison
EQS vs CLRB Comparison
Compare EQS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- CLRB
- Stock Information
- Founded
- EQS 1991
- CLRB 2002
- Country
- EQS United States
- CLRB United States
- Employees
- EQS N/A
- CLRB N/A
- Industry
- EQS Finance Companies
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- CLRB Health Care
- Exchange
- EQS Nasdaq
- CLRB Nasdaq
- Market Cap
- EQS 13.9M
- CLRB 12.5M
- IPO Year
- EQS N/A
- CLRB N/A
- Fundamental
- Price
- EQS $0.85
- CLRB $0.25
- Analyst Decision
- EQS
- CLRB Hold
- Analyst Count
- EQS 0
- CLRB 2
- Target Price
- EQS N/A
- CLRB N/A
- AVG Volume (30 Days)
- EQS 5.3K
- CLRB 729.7K
- Earning Date
- EQS 01-01-0001
- CLRB 05-13-2025
- Dividend Yield
- EQS N/A
- CLRB N/A
- EPS Growth
- EQS N/A
- CLRB N/A
- EPS
- EQS N/A
- CLRB N/A
- Revenue
- EQS $1,274,000.00
- CLRB N/A
- Revenue This Year
- EQS N/A
- CLRB N/A
- Revenue Next Year
- EQS N/A
- CLRB N/A
- P/E Ratio
- EQS N/A
- CLRB N/A
- Revenue Growth
- EQS 411.65
- CLRB N/A
- 52 Week Low
- EQS $0.87
- CLRB $0.22
- 52 Week High
- EQS $1.53
- CLRB $3.49
- Technical
- Relative Strength Index (RSI)
- EQS 37.58
- CLRB 39.17
- Support Level
- EQS $0.74
- CLRB $0.23
- Resistance Level
- EQS $1.01
- CLRB $0.27
- Average True Range (ATR)
- EQS 0.05
- CLRB 0.02
- MACD
- EQS -0.01
- CLRB -0.00
- Stochastic Oscillator
- EQS 33.94
- CLRB 15.12
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.